Approval Probability 71%
TA Base Rate26%
Adjusted LOA41%
ML RiskLOW_RISK
| NCT ID | Title | Phase | Status | Enrollment | Velocity | Design | Start | Completion | Last Updated | Sites | Countries |
|---|---|---|---|---|---|---|---|---|---|---|---|
| NCT02475213 | Safety Study of Enoblituzumab (MGA271) in Combination With Pembrolizumab or MGA012 in Refractory Cancer | PHASE1 | COMPLETED | 146 | — | — | Jul 1, 2015 | Aug 18, 2021 | Aug 11, 2025 | 20 | United States |
Dose-limiting toxicities are severe side effects related to study treatment that may cause dose interruptions, dose reductions, or withdrawal of treatment.
| Arm | Type | Description |
|---|---|---|
| Cohort 1 | EXPERIMENTAL | Enoblituzumab 3 mg/kg IV weekly plus pembrolizumab 2 mg/kg IV every 3 weeks |
| Cohort 2 | EXPERIMENTAL | Enoblituzumab 10 mg/kg IV weekly plus pembrolizumab 2 mg/kg IV every 3 weeks |
| Cohort 3 | EXPERIMENTAL | Enoblituzumab 15 mg/kg IV weekly plus pembrolizumab 2 mg/kg IV every 3 weeks |
| Cohort 4 | EXPERIMENTAL | Enoblituzumab 15 mg/kg IV plus retifanlimab 375 mg IV every 3 weeks |
| Melanoma Cohort | EXPERIMENTAL | Enoblituzumab 15 mg/kg IV weekly plus pembrolizumab 2 mg/kg IV every 3 weeks |
| Urothelial Cancer Cohort | EXPERIMENTAL | Enoblituzumab 15 mg/kg IV weekly plus pembrolizumab 2 mg/kg IV every 3 weeks |
| Non-small Cell Cancer (NSCLC) Cohort | EXPERIMENTAL | Enoblituzumab 15 mg/kg IV weekly plus pembrolizumab 2 mg/kg IV every 3 weeks |
| Squamous Cell Cancer of Head and Neck (SCCHN) Cohort | EXPERIMENTAL | Enoblituzumab 15 mg/kg IV weekly plus pembrolizumab 2 mg/kg IV every 3 weeks |
| Name | Type | Description |
|---|---|---|
| Enoblituzumab Schedule 1 | BIOLOGICAL | enoblituzumab is administered by IV infusion once per week for up to 51 doses. |
| Pembrolizumab | BIOLOGICAL | Pembrolizumab is administered by IV infusion every 3 weeks for up to 17 doses. |
| Enoblituzumab Schedule 2 | BIOLOGICAL | Enoblituzumab is administered by IV infusion every 3 weeks for up to 17 doses |
| retifanlimab | BIOLOGICAL | Retifanlimab is administered by IV infusion every 3 weeks for up to 17 doses |
Inclusion Criteria: * To enroll on cohorts 1-4, participants must have a histologically-proven, previously treated, unresectable, locally advanced or metastatic mesothelioma, urothelial cancer, thyroid cancer, pancreatic cancer, ovarian cancer, colon cancer, prostate cancer, soft tissue sarcoma, tr...